Last reviewed · How we verify
14C-Labeled Vemurafenib
At a glance
| Generic name | 14C-Labeled Vemurafenib |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 14C-Labeled Vemurafenib CI brief — competitive landscape report
- 14C-Labeled Vemurafenib updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI